Home
Discovering biology’s relationships, curing disease.
We are an end-to-end biotech developing transformational medicines, with technology at our core.
Our ambition is to understand human biology in an unprecedented way; discovering therapies that will treat some of life's most devastating diseases. We leverage single-cell multi-omics directly from patient tissue, functional assays and machine learning to drive at disease understanding — from cause to cure.
Our science
Medicines born from high-resolution biology, machine learning and clinical insights.
Our Lab-in-the-Loop seamlessly integrates single-cell analysis, genomics and machine learning. We have developed powerful technologies which we apply to select druggable targets and develop transformational medicines.
Our team
Interdisciplinary collaboration.
Immense impact.
Relation is led by experienced drug developers, computational scientists and entrepreneurs with experience across biotech, pharma, venture and academic research. We have a hunger to transform drug development as we know it — because the patient is waiting.
Timeline
-
Jan 2020
Company founded by Charles Roberts, Benjamin Swerner and Jake Taylor-King
-
Sept 2020
Relation, Yoshua Bengio, Mila and Scripps Research awarded grant from Bill and Melinda Gates Foundation
-
Mar 2022
Relation awarded access to NVIDIA's CAMBRIDGE-1, the UK's most powerful supercomputer, to power digital biology breakthroughs
-
April 2022
David Roblin moves from Non-Executive Director to CEO
-
June 2022
$25M raised led by DCVC and Magnetic
-
Feb 2023
Nobel laureate Sir Paul Nurse opens Relation Labs
-
March 2023
Relation announces osteoporosis as its first indication
-
March 2024
Relation announces $60M seed financing closure
Join our team.
We are seeking world-class talent across biology, machine learning and drug discovery. Explore our opportunities here.
Read our news
Read more-
Relation announces two strategic collaborations with GSK to advance therapeutics for fibrotic diseases and osteoarthritis | Global news wire
Global New wire | Relation announces strategic collaborations with GSK
In the news 10 Dec 2024
-
It's the biology stupid, Relation and GSK team up on fibrosis osteoarthritis | Endpoints
Endpoints | its-the-biology-stupid-relation-and-gsk-team-up-on-fibrosis-osteoarthritis
In the news 10 Dec 2024
-
The Times | GSK puts its faith in London biotech firm with $300m deal
The Times London
Press release 10 Dec 2024
-
A community effort to track commercial single-cell and spatial ’omic technologies and business trends
Nature Biotechnology
Scientific publication 17 Jul 2024